Agalsidase alfa (Replagal®; TKT Europe, 5S AB-Danderyd, Sweden) was administered intravenously to female patients with FD in an open-label, single-center study by Bähner and colleagues to assess its safety, effectiveness, and pharmacokinetics [167]. This evidence concerns the gene GLA and Fabry disease.